Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/12/21 | 8-K | Current report filing |
|
   |
8 |
| 04/08/21 | 8-K | Current report filing |
|
|
47 |
| 04/07/21 | 8-K | Current report filing |
|
|
3 |
| 03/23/21 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
15 | |
| 03/18/21 | 3 | Initial statement of beneficial ownership of securities |
|
3 | |
| 03/16/21 | 8-K | Current report filing |
|
|
8 |
| 03/08/21 | 8-K | Current report filing |
|
|
45 |
| 03/03/21 | S-3 | Registration statement for specified transactions by certain issuers |
|
116 | |
| 03/02/21 | 8-K | Current report filing |
|
|
18 |
| 02/18/21 | UPLOAD | SEC-generated letter |
|
3 |
